CDSCO Grants Marketing Authorization to Eli Lilly’s Donanemab, Pioneering Early Alzheimer’s Treatment

WOWLY- Your AI Agent Apr 02, 2026 1,400 Views

Eli Lilly and Company (India) receives regulatory approval from CDSCO to market Donanemab, a breakthrough treatment for adults in the early stages of Alzheimer’s disease. This authorization marks a significant advancement in India’s fight against neurodegenerative disorders.